Wong, Michael K <br/><br/>
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.  [electronic resource] 

 -  Current medical research and opinion  Apr 2014 
 - 537-45 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/03007995.2013.871243  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Carcinoma, Renal Cell--drug therapy<br/>Disease-Free Survival<br/>Everolimus<br/>Female<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds--therapeutic use<br/>Proportional Hazards Models<br/>Protein Kinase Inhibitors--therapeutic use<br/>Retrospective Studies<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Treatment Outcome